99 related articles for article (PubMed ID: 15576971)
1. [Bisphosphonates].
Matsumoto T
Clin Calcium; 2004 Jan; 14(1):145-52. PubMed ID: 15576971
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
3. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
Takeuchi Y
Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
[TBL] [Abstract][Full Text] [Related]
4. Role of bisphosphonates and calcitonin in the prevention and treatment of osteoporosis.
Woo T; Adachi JD
Best Pract Res Clin Rheumatol; 2001 Jul; 15(3):469-81. PubMed ID: 11485341
[TBL] [Abstract][Full Text] [Related]
5. Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies.
Jansen JP; Bergman GJ; Huels J; Olson M
Curr Med Res Opin; 2009 Aug; 25(8):1861-8. PubMed ID: 19530978
[TBL] [Abstract][Full Text] [Related]
6. [Treatment with bisphosphonates: daily or once-weekly oral administration and intravenous injection].
Kitahama S; Ishii T; Wada S
Clin Calcium; 2005 Apr; 15(4):649-54. PubMed ID: 15802779
[TBL] [Abstract][Full Text] [Related]
7. [Anabolic treatment for osteoporosis: PTH treatment].
Kaji H; Sugimoto T
Clin Calcium; 2006 Sep; 16(9):1480-85. PubMed ID: 16951472
[TBL] [Abstract][Full Text] [Related]
8. Recognition of women at risk for fracture and intervention with fast-acting therapies.
Derman R
Int J Fertil Womens Med; 2006; 51(4):183-90. PubMed ID: 17184104
[TBL] [Abstract][Full Text] [Related]
9. Combination and sequential therapy with PTH and bisphosphonates.
Bauer DC
J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):407. PubMed ID: 15758282
[No Abstract] [Full Text] [Related]
10. [Prevention of osteoporotic fracture by pharmaceutical interventions].
Nakamura T
Clin Calcium; 2006 Dec; 16(12):1961-67. PubMed ID: 17142925
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
12. Drug insight: Existing and emerging therapies for osteoporosis.
Mulder JE; Kolatkar NS; LeBoff MS
Nat Clin Pract Endocrinol Metab; 2006 Dec; 2(12):670-80. PubMed ID: 17143314
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid hormone update.
Hamann KL; Lane NE
Rheum Dis Clin North Am; 2006 Nov; 32(4):703-19. PubMed ID: 17288973
[TBL] [Abstract][Full Text] [Related]
14. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study.
van den Boogaard CH; Breekveldt-Postma NS; Borggreve SE; Goettsch WG; Herings RM
Curr Med Res Opin; 2006 Sep; 22(9):1757-64. PubMed ID: 16968579
[TBL] [Abstract][Full Text] [Related]
15. Update of current therapeutic options for the treatment of postmenopausal osteoporosis.
Epstein S
Clin Ther; 2006 Feb; 28(2):151-73. PubMed ID: 16678639
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
17. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
Soen S
Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Inderjeeth CA; Foo AC; Lai MM; Glendenning P
Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
[TBL] [Abstract][Full Text] [Related]
20. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
